Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma

[1]  S. Hanada,et al.  Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T‐cell leukaemia‐lymphoma , 2018, British journal of haematology.

[2]  R. Ueda,et al.  Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and II studies , 2017, Cancer science.

[3]  Takeshi Takahashi,et al.  Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia–lymphoma in Japan: interim results of postmarketing all-case surveillance , 2017, International Journal of Hematology.

[4]  K. Shimoda,et al.  Effects of mogamulizumab in adult T‐cell leukemia/lymphoma in clinical practice , 2017, European journal of haematology.

[5]  Kazuya Sato,et al.  A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T‐Cell Leukemia/Lymphoma , 2017, Clinical lymphoma, myeloma & leukemia.

[6]  M. Ogura,et al.  Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Nomura,et al.  Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long‐term survivors of aggressive adult T‐cell leukaemia‐lymphoma (JCOG0902A) , 2014, British journal of haematology.

[8]  K. Ohshima,et al.  [Outcome of patients with relapsed/refractory adult T-cell leukemia-lymphoma after salvage therapy]. , 2013, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[9]  R. Ueda,et al.  Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Yamanaka,et al.  Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Ueda,et al.  VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Iida,et al.  Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  M. Tomonaga,et al.  Deoxycoformycin-Containing Combination Chemotherapy for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study (JCOG9109) , 2003, International journal of hematology.

[14]  K. Matsushima,et al.  Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. , 2002, Blood.

[15]  M. Tomonaga,et al.  A new G‐CSF‐supported combination chemotherapy, LSG15, for adult T‐cell leukaemia‐lymphoma: Japan Clinical Oncology Group Study 9303 , 2001, British journal of haematology.

[16]  M. Shimoyama,et al.  Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.